drugset
drugset / Trial / NCT03709056

A Study Evaluating the Efficacy and Safety of HSK3486

NCT03709056 ↗

Phase 2 Completed 94 enrolled Sichuan Haisco Pharmaceutical Group Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

A double-blind, randomized, active controlled, multi-center, parallel group study comparing HSK3486 with Propofol, in patients undergoing a colonoscopy.

Timeline

Start
2017-12-14
Primary completion
2018-02-02
Completion
2018-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cipepofol Small molecule 0.113 mg/kg Intravenous
Subject Cipepofol Small molecule 0.15 mg/kg Intravenous
Subject Cipepofol Small molecule 0.2 mg/kg Intravenous
Comparator Propofol Small molecule 0.75 mg/kg Intravenous
Comparator Propofol Small molecule 1 mg/kg Intravenous

Indications

No indication recorded.